Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.54 |
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | INSR | P06213 | 1/20 | 0.54 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | SNCA | P37840 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11776645 | 0.89 | MAPT (0.57) | MAPTRAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL26467451 | 0.89 | MAPT (0.57) | MAPTRAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL26467442 | 0.84 | RAB9A (0.49) | MAPTRAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL26467465 | 0.83 | MAPT (0.49) | MAPTRAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21889377 | 0.83 | MEN1 (0.56) | MAPTRAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30434981 | 0.83 | MEN1 (0.56) | MAPTRAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL26094294 | 0.82 | MEN1 (0.66) | MAPTRAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL319385 | 0.80 | MEN1 (0.77) | MAPTRAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29559249 | 0.80 | MEN1 (0.77) | MAPTRAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL319386 | 0.80 | MEN1 (0.77) | MAPTRAB9AMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133538-A1 | TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133538-A1 | TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133538-A1 | TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 | MAPT, PSEN1, PSEN2 | MAPT 1/4885RAB9A 1002/4885MEN1 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.